Auto-immune disease Target
What is Auto-immune disease?
Autoimmune diseases arise when the immune system mistakenly targets the body's tissues, causing inflammation and damage. Their precise triggers are unclear, but genetics, environment, and hormones are influential. Common examples include:
Rheumatoid arthritis: Immune system targets joints.
Systemic lupus erythematosus (SLE): Affects skin, joints, kidneys, brain, etc.
Type 1 diabetes: Immune system attacks insulin-producing pancreatic cells.
Exploring Therapeutic Strategies by Mechanism of Action (MOA)
Autoimmune diseases' MOAs classify how the immune system damages self-tissues, aiding diagnosis, treatment, and research:
Cell-Mediated Immunity vs. Humoral Immunity
Cell-Mediated Immunity: T cells directly attack the body's cells. E.g., Type 1 diabetes (T cells destroy pancreatic beta cells), and psoriasis (T cells target skin cells).
Humoral Immunity: B cells produce autoantibodies targeting tissues. E.g., Rheumatoid Arthritis (autoantibodies form immune complexes in joints), and SLE (broad autoantibody range causes systemic symptoms).
Organ-Specific vs. Systemic Autoimmune Diseases
Organ-Specific: Immune response targets specific organs/tissues, such as the thyroid gland in Hashimoto's thyroiditis, or the neuromuscular junction in Myasthenia Gravis.
Systemic: Multiple organs/systems affected, as with SLE impacting skin, joints, kidneys, brain, and Rheumatoid Arthritis potentially affecting lungs and heart as well.
Inflammatory vs. Non-Inflammatory
Inflammatory: Chronic inflammation, often with cytokine production causing tissue damage, as in Crohn's disease (gastrointestinal tract inflammation) and Rheumatoid Arthritis (joint inflammation).
Non-Inflammatory: Some lack overt inflammation but cause functional impairment or tissue damage, such as certain autoimmune-mediated neuropathies, where the issue is functional interference, not inflammation.
Pathway of Immune Activation
T-Cell Activation: Autoreactive T cells are activated against self-antigens, significant in Type 1 diabetes and Multiple Sclerosis.
B-Cell Activation and Autoantibody Production: E.g., SLE and Rheumatoid Arthritis, where autoantibodies are pathogenic or form damaging immune complexes.
Cytokine Profile
Th1/Th17 Dominance: Diseases characterized by Th1 or Th17 cells, producing cytokines leading to inflammation and autoimmunity, observed in Type 1 diabetes (Th1) and psoriasis (Th17).
Regulatory T Cell (Treg) Dysfunction: Failure/reduction in Treg function, essential for immune tolerance to self-antigens, leads to uncontrolled autoimmunity.
Detailed Insights into Therapeutic and Diagnostic Targets of MOA-Based Strategies
MOA Category | Target/Biomarker | Target ID | Therapeutic Use | Diagnostic Use |
Cell-Mediated Immunity | CD4 | GM-T10191 | Monoclonal antibodies to modulate T cell responses | CD4+ T cell count in HIV/AIDS; indicates T cell involvement |
CD8 | P01732 | Modulating CD8+ T cell activity | Assessing CD8+ T cell activation | |
Humoral Immunity | Autoantibodies | Varies | Plasma exchange, immunosuppressants, B cell depletion | Detection of specific autoantibodies for diagnosis |
Organ-Specific Diseases | GAD2 (GAD65) | GM-T22128 | - | Anti-GAD65 antibodies as markers for type 1 diabetes, Stiff-Person Syndrome |
Systemic Diseases | Anti-nuclear antibodies (ANAs) | Varies | - | Broad diagnostic tool for diseases like SLE |
Inflammatory | TNF | GM-T20178 | Anti-TNF therapies (e.g., Infliximab, Adalimumab) | Elevated TNF-伪 levels indicate active inflammation |
Pathway of Immune Activation | IL-17 | GM-T22095 | IL-17 inhibitors (e.g., Secukinumab) | Elevated IL-17 levels suggest Th17 involvement |